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Mutations in both acid-β-glucosidase (GCase) and saposin C lead to Gaucher disease, the most common lysosomal storage
disorder. The past several years have seen an explosion of structural and biochemical information for these proteins, which have
providednewinsightintothebiologyandpathogenesis ofGaucher disease, aswell asopportunitiesfornew therapeuticdirections.
Nearly 20 crystal structures of GCase are now available, from diﬀerent heterologous sources, complexed with diﬀerent ligands in
theactivesite,indiﬀerentglycosylationstates,aswellasonethatharborsaprevalentdisease-causingmutation,N370S.Forsaposin
C, two NMR and 3 crystal structures have been solved, each with its unique snapshot. This review focuses on the details of these
structures to highlight salient common and disparate features that contribute to our current state of knowledge of this complex
orphan disease.
1.Introduction
Gaucher disease (GD) is a human catabolic disorder mainly
due to mutations in the gene encoding for the lysosomal
enzyme acid-β-glucosidase (GCase) [1]. As a consequence of
an amino acid substitution in the resultant protein, its major
substrate, N-acyl-sphingosyl-1-O-β-D-glucoside (GlcCer),
accumulates, is engulfed in macrophages, and clinically
results in enlarged organs, splenomegaly, hepatomegaly, and,
in severe Gaucher cases, disorders of the central nervous
systemandbrain.GDoccursin1:10000birthsinthegeneral
population but is much more prevalent in the Ashkenazi
Jewish population, where its incidence is estimated as high
as 1:200 [1]. Therapies only exist for non-neuronopathic
Gaucher disease [2], which include enzyme replacement
therapy using recombinant enzyme [3], and substrate reduc-
tion therapy using a small molecule inhibitor of a GlcCer
biosynthetic enzyme [4].
Mature GCase is a glycoprotein consisting of 497 amino
acids derived from a precursor that is proteolyzed prior
to lysosomal traﬃcking [5, 6]. The wild type enzyme is
traﬃcked via a pathway independent of the more typical
mannose receptor pathway [7] in a recently discovered asso-
ciation with lysosomal integral membrane protein II (LIMP-
II) [8]. However, since patients with mutations in LIMP-
II do not exactly replicate Gaucher symptoms [9], other
lysosomal traﬃcking pathways for GCase may also exist. By
comparison, recombinant, therapeutic, GCase is engineered
for lysosomal targeting via the mannose receptor pathway
and is decorated with mannose-6-phosphate (M6P) [10].
Almost 300 diﬀerent point mutations GCase are known
to cause GD, by far the most prevalent of which are missense
mutations [11]. When an amino substitution is introduced,
mutant GCase is retained in the ER where it is targeted
to degradation, leading to a reduction in enzyme levels
[12–15]. However, when expressed in the laboratory, many
mutant GCase variants, such as N370S predominant among
Ashkenazi Jews, produce stable enzymes with residual,
albeit impaired, activity [16]. These ﬁndings have fueled
new therapeutic eﬀorts to decrease degradation and rescue2 Enzyme Research
mutant GCase lysosomal traﬃcking with small molecules,
which may cross the blood brain barrier and be therapeutic
for neuronopathic GD [17–20].
GCase falls into the large family of glycoside hydrolases,
well-studiedenzymesfoundthroughoutbiologythatusecat-
alyticaspartateorglutamatesforgeneralacid/basehydrolysis
[21]. Human lysosomal GCase belongs to the GH30 fam-
ily (http://www.cazy.org/Glycoside-Hydrolases.html)[ 22],
enzymes in which use a chemical mechanism to retain the
strereochemistry of the substrate. For GCase, the catalytic
nucleophile is Glu 340, identiﬁed from a mass spectrometric
adduct using a covalent inhibitor [23], and the general
acid/base residue is Glu 235, identiﬁed unambiguously from
the GCase structure [24]. The mechanism for retaining β-
glucosidases [25, 26] uses double-displacement acid/base
chemistry involving nucleophilic attack of a deprotonated
glutamate to form a glycosyl-enzyme intermediate, followed
by hydrolysis of the adduct. This reaction is proposed to
proceed through two oxocarbenium ion-like planar tran-
sition states [21], and the pKa of each carboxylate tailors
the side chain for its particular function [27, 28]. In vitro,
GCase has been assayed using radiolabeled GlcCer and thin
liquidchromatographicseparation[28]ormodelﬂuor escent
substrates [29]. The wild-type GCase sources discussed in
this review exhibit a Km for various substates in the low
to mid μMr a n g e ,a n dVmax of ∼0.5μM/min [29, 30].
Among disease-causing mutants tested [16, 31], the turnover
number, kcat, is lower than wild-type GCase, and, consistent
with this observation, the N370S-mutant GCase speciﬁcally
exhibits a reduced Vmax and increased Km [32].
In the lysosome, the wild-type GCase is membrane-
associated and requires the activator protein saposin C
(SapC) for catalysis [39]; mutations in SapC also lead to
GD [40, 41]. Originally isolated from the spleen of Gaucher
patient [39], SapC derives from a prosaposin cursor [42]a n d
increases substrate hydrolytic rates of GCase in vitro [40, 43,
44] .T h i sp r o c e s si sb o t hr e v e r s i b l ea n dp H - c o n t r o l l e d[ 39,
45].SapCremodelsthelipidmembrane[46,47],presumably
to assist GCase in accessing the short headgroup of GlcCer,
likelyviaamultistepmechanism[48,49].Inparticular,SapC
is believed to modulate the lysosomal membrane structure
in a detergent-like solubilizing manner [50]. Recent atomic
force microscopy and other spectroscopic studies reveal that
GCase associates with SapC at the membrane surface [46],
although its explicit binding modes are not well-understood.
Many excellent reviews exist on GCase and SapC bio-
chemistry, as well as clinical aspects of GD including its
current and future treatment. Several are listed here and
throughout this document for further reading [1, 2, 51–
59]. This review focuses on a comparison of the available
structures of GCase and SapC and their contributions to our
current state of knowledge of the biology and pathogenesis
of this heterogeneous orphan disease.
2. Structureof GCase
2.1. Protein Sources. To date, nearly 20 crystal structures
o fG C a s eh a v eb e e ns o l v e du n d e rd i ﬀerent conditions,
including 12 more since the ﬁrst review article on GCase
structures was published in 2008 [53]. The source of
enzyme is the same as that used in, or in development
for, patient treatment: Cerezyme (puriﬁed from CHO cells),
Taliglucerase-alfa (puriﬁed from carrot cells, prGCase), or
Velaglucerase-alfa (puriﬁed from human cell line). The ﬁrst
two sources have an inocuous single mutation introduced
near the C-terminus, R495H, not present in Velaglucerase-
alfa [30]. The ﬁrst structure of mutant GCase, N370S,
expressed in baculovirus, became available in late 2010 [32].
A list of GCase structures available in the protein databank
(PDB) (http://www.rcsb.org/) at the time of the writing of
this review is presented in Table 1.
2.2. Crystallization Conditions. Three main crystallization
conditions have been reported (Table 1). The ﬁrst two, uti-
lized to obtain the majority of structures, including all those
for Cerezyme and for Velaglucerase-alfa, employs vapor
diﬀusion and similar high-salt cocktails. One condition uses
low pH and molar concentration of ammonium sulfate
[24] whereas the second uses near molar concentrations of
phosphate and a variety of pH buﬀers [35]. Both of these
conditions lead to crystals with a lattice of approximate
dimensions 109 ˚ A × 285 ˚ A × 91 ˚ A that belong to either the
orthorhombic (all angles 90◦) space group C2221 with two
independent copies of GCase in the asymmetric unit or the
monoclinic (β angle = ∼109◦)P 2 1 with four such GCase
molecules in the asymmetric unit. The lattice selection
depends on how the enzyme is packed in the crystal and
determines which molecules are considered equivalent by
symmetry.Thus,inC2221,thehighersymmetryspacegroup,
there is additional averaging over molecules in the unit cell
compared to the case of P21, leading to 2 or 4 independent
v i e w so fG C a s ef o re a c hr e p o r t e ds t r u c t u r e ,r e s p e c t i v e l y .T h e
ﬁrst GCase structure was solved by obtaining experimental
phases from a bound mercury ion [24], whereas subsequent
structures have been solved either by molecular replacement
of this initial structure [29, 30, 32, 34, 35] or by rigid body
reﬁnement in the case of isomorphous crystals [33, 36–
38]. The third crystallization condition uses the microbatch
method under oil and contains polyethylene glycol 3350 as
the main precipitant [36]. Thus far, only prGCase appears
to crystallize using this cocktail, which has been particularly
successful in capturing structures with hydrophobic active-
site-directed inhibitors (see what follows) [36, 37]. In this
case,thelatticebelongstothespacegroupP21 withtwoinde-
pendent views of GCase in the asymmetric unit and lattice
parameters of approximately 68 ˚ A, 97 ˚ A, 83 ˚ A, β = 104◦.
2.3. Overall Structure. Regardless of crystallization condi-
tion, molecules in asymmetric units from all GCase sources
exhibit root mean squared diﬀerences (rmsd) of ∼0.6 ˚ A,
indicating that the views of GCase are nearly identical.
GCasecomprisesthreediscontinuousdomains(Figure1(a)):
an antiparallel β-sheet (Domain 1), a triose phosphate
isomerase(TIM)barrelharboringtheactivesite(Domain2),
andan8-strandedβ-barrel(Domain3).Domains2and3are
seen in similar relative orientations in other hydrolases, such
as in α-galactosidase A, mutations in which cause another
lysosomalstoragedisorder,Fabrydisease,evenintheabsenceEnzyme Research 3
Table 1: Crystal structures reported for GCase.
PDB code Enzyme source Deglycosylated? Active site Crystallization condition pH Ref.
1OGS CHO/Cerezyme PDa Sulfate Ammonium sulfate, Guanidinium HCl, KCl,
acetate buﬀer, cryoprotected with glycerol 4.6 [24]
1Y7V CHO/Cerezyme PD CBE Same as 1OGS, soaking overnight with 1mM CBE,
c r y o p r o t e c t e dw i t hg l y c e r o l 4.6 [33]
2F61 CHO/Cerezyme PD Ammonium sulfate, citrate buﬀer, magnesium
chloride 6[ 16]
2J25 CHO/Cerezyme No Ammonium sulfate, bis-tris buﬀer 5.5 [34]
2NSX CHO/Cerezyme PD IFG Same as 1OGS, soaking for 10  with 0.2mM IFG 4.5 [35]
2NT0 CHO/Cerezyme PD Glycerol Same as 1OGS 4.5 [35]
2NT1 CHO/Cerezyme PD Na, K Dihydrogen phosphate, Hepes buﬀer,
lithium sulfate cryoprotectant 7.5 [35]
2V3D Plant/Taliglucerase-alfa No NB-DNJ Ammonium sulfate, Tris buﬀer, PEG 3350;
cocrystallization with ligand 6.5 [36]
2V3E Plant/Taliglucerase-alfa No NN-DNJ Ammonium acetate, Hepes buﬀer, PEG 3350;
cocrystallization with ligand 7.5 [36]
2V3F Plant/Taliglucerase-alfa No N/A Ammonium sulfate, bis-Tris buﬀer, hexamine
cobalt(III) chloride, PEG 3350 6.5 [29]
2VT0 Plant1 N/Ab N/A Ammonium sulfate, Tris buﬀer, PEG 3350 6.5 N/A
2WCG Plant/Taliglucerase-alfa No
N-octyl(cyclic
guanidine)-
nojirimycin
Same as 2V3D, cocrystallization with ligand 6.5 [37]
2WKL Human cell
line/Velagucerase-alfa No Ammonium sulfate, Hepes buﬀer, PEG 8000,
ethylene glycol cryoprotectant 7[ 30]
3GXD CHO/Cerezyme PD Na, K Dihydrogen phosphate, acetate buﬀer,
lithium sulfate cryoprotectant 4.5 [38]
3GXF CHO/Cerezyme PD IFG
Na, K Dihydrogen phosphate, Hepes buﬀer,
glycerol cryoprotectant, soaking for 10  with
0.5mM IFG
7.5 [38]
3GXI CHO/Cerezyme PD Na, K Dihydrogen phosphate, citrate buﬀer,
lithium sulfate cryoprotectant 5.5 [38]
3GXM CHO/Cerezyme PD Same as 1OGS 4.5 [38]
3KE0 Baculovirus
(N370S-GCase) PD Same as 1OGS 5.4 [32]
3KEH Baculovirus
(N370S-GCase) PD Na, K Dihydrogen phosphate, Hepes buﬀer,
glycerol cryoprotectant 7.4 [32]
aPD: partially glycosylated
bN/A: Not applicable or not available.
sequencesimilarity[38].Importantly,asinα-galactosidaseA
[60], mutations are found throughout the three-dimensional
structure of GCase and are not localized to a particular
patch on the enzyme [24] (Figure 2 and see the following
discussion).
Just four diﬀerent enzyme structures are available for the
GH30 glycosidase family. Domains 2 and 3 are common to
these orthologs (Figure 1(a)), but the structures diverge in
the region of Domain 1 (Figure 1(a), arrow 1) and its imme-
diateenvirons(Figure1(b)).ForbothGH30xylanasessolved
todate(pdbcode3KL0s[61],1NOF[62],formerlymembers
of GH5 family [61]), Domain 1 is absent, and a nearby loop
that covers the GCase active site (see what follows) is also
missing (Figure 1(b), top panel). A more similar structural
homolog (PDB code 2WNW), S. typhimurium SrfJ involved
in bacterial pathogenicity [63], has a truncated Domain
1. A β-hairpin is followed by the aforementioned GCase
loop (Figure 1(b), lower panel), albeit with low sequence
conservation (see Figure 1(c), Phe/Cys substitution). The
precise substrate of SrfJ remains to be elucidated, but it
seems likely that SrfJ may recognize alkyl chain containing
glycosides, similar to GCase [63]. One region unique to
GCase is near the presumed general acid-base residue Glu
235 (see the following), which takes on a helical conforma-
tion. All three other GH30 structures do not have deﬁned
secondary structure features in this region (Figure 1(a),
arrow 2). Although implications for catalysis are not known,
the proximity to the active site, which is otherwise very
similar and highly conserved (Figure 1(c)), suggests that this
region may assist in tuning chemistry in the active site.
2.4. Active Site. At minimum, the active site consists of the
residues known to be involved in catalysis, namely, Glu 340,
the nucleophile, Glu 235, the presumptive general acid-base4 Enzyme Research
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Figure 1: Superposition of GH30 family member structures. Cartoon representation: apo GCase (PDB code 3GXD), raspberry red;
xylanases, yellow (PDB code 1NOF) and blue (PDB code 3LK0); SrfJ, green (pdb code 2WNW). (a) Overall structures with domains labeled.
Arrows 1, 2: deviations in Domains 1 and 2, respectively (see text). (b) Top: comparison of GCase and xylanases (blue, yellow) in Domain
1 region; bottom: comparison of GCase and SrfJ (green) in Domain 1 region. (c) Active site region (Domain 2) with select amino acid side
chains depicted in ball-and-stick.
G202R
D409H
V394F
E340
E235
N370S
R496C
R463C L444P
Figure 2: Location of just six of over 200 missense mutations
known to cause GD mapped onto the GCase structure. Yellow: site
of amino acid substitution; raspberry red: catalytic residues Glu 235
and Glu 340.
residuelocated5 ˚ AawayfromGlu340,plusresiduesinvolved
in stabilizing GlcCer in the active site. This region encom-
passesbothawell-deﬁnedbindingsitefortheglucosemoiety
w i t h i nD o m a i n2( F i g u r e1(a)) whereas the ceramide region
is less well understood (see the following discussion below).
Residues that line the glucose-binding region but are not
directly involved in catalysis include Arg 120, Asp 127, Phe
128, Trp 179, Asn 234, Tyr 244, Phe 246, Tyr 313, Cys 342,
Ser 345, Trp 381, Asn 396, Phe 397, and Val 398 (Figure 3(a);
some residues are omitted from the image for clarity). The
aromatic side chains are thought to be involved in substrate
recognition [64] and several polar residues form hydrogen
bonding interactions with substrate. Many of the residues
are located on the interior of GCase within well-deﬁned
secondary structural elements and remain essentially static
regardless of what may be bound in the active site. Other
residues, including Tyr 313, Asp 315, Asn 396, and Phe 397,
among others, are sensitive to ligand binding, as discussed
below. In the apo GCase active site, these residues have high
thermalB-factors,indicatingthatcrystallographicallyrelated
residues in this region of the protein sample a number of
diﬀerent conformations, and Figure 3(b) is just an average
of several accessible to enzyme [35, 38].
As a result of a component in the crystallization cocktail,
two ligands have serendipitously appeared bound in the
active site. A sulfate anion was modeled in the active site of
theﬁrstGCasestructure[24].Arationaleforthisassignment
is the high concentrations of ammonium sulfate in the
crystallization condition. Assuming that the sulfate anion
is partially protonated, which is likely given the pH of
the crystallization condition, hydrogen bonding interactions
with catalytic residue of GCase are present (Figure 3(c)). In
a later structure at slightly higher resolution but using the
same crystallization conditions, an uncharged, polar glycerol
molecule is modeled in the active site [35] (Figure 3(d)).
Glycerol is present at 20% in the mother liquor used to pro-
tect the crystal upon cryo-cooling before data collection and
a characteristic “w” shape of glycerol was clearly apparent
in diﬀerence density maps [35]. Like what is expected for
the hydroxyl substituents of glucose, glycerol is stabilized by
hydrogen bonding interactions with polar residues in the
activesite(Figure3(d)).Itispossiblethatdiﬀerencesincryo-
cooling procedures led to diﬀerent molecules bound in the
GCase active site. A “true” apo GCase was achieved by using
Li2SO4 for cryprotection instead of glycerol [38]; in this
structure only waters appear in the active site, and the GCase
scaﬀold remained essentially unchanged (Figure 3(b)).Enzyme Research 5
D127 N396
F397
W179
N234 E340
E235 Y313
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 3: Active sites from diﬀerent GCase structures. (a) Superposition of structures presented in (b)–(h) with residues labeled and any
ligands omitted. (b) Apo GCase, (c) sulfate-bound GCase (PDB code 1OGS), (d) glycerol-bound GCase (PDB code 1NT1), (e) CBE-bound
GCase (PDB code 1Y7V), (f) IFG-bound GCase (PDB code 1NT1), (g) NB-DNJ (PDB code 2V3D), and (h) N-octyl(cyclic guanidine)-
nojirimycin (PDB code 2WCG). Dashed lines indicate hydrogen bonding interactions (2.5–3.5 ˚ A distance from N, O atoms).
GCasecrystalstructur esha v ebeensol v edwithnumer ous
intentional ligands as well, to investigate conformational
changes in the active site that may arise upon their binding
and help exploit this knowledge for small molecule drug
development [65, 66]. In the ﬁrst such investigation, the
known suicide inhibitor, 1,2-anhydro-myo-inositol (CBE),
was added to preformed GCase crystals [33] (Figure 3(e)).
Though the overall enzyme structure is nearly identical to
previousstructures,severalfeaturesareseenintheactivesite.
Most importantly, the observed adduct ﬁrmly established
that enzyme inactivation by CBE is a result of its binding
to the active site, and in particular, its covalent attachment
to nucleophile Glu 340 and not to any other residues
[33], conﬁrming previous mass spectrometry data [23]. The
structure is also consistent with the proposed enzymatic
mechanism, which involves protonating the epoxide oxygen
by Glu 235 followed by nucleophilic attack of the myo-
inositol ring by Glu 340, forming the nucleophile-myo-
inositol ester bond [67]. The once-epoxide oxygen is pointed
toward Glu 235 in the product myo-inositol but might also
be stabilized by hydrogen bonding interactions with Asn
234 (not shown). Unexpectedly, the product is in a boat
conformationwhereachairconformationwasexpected[33].
Last, it is in this structure that Asn 396 was ﬁrst observed in
the active site of GCase, replacing the position of Phe 397,
where it assists in holding myo-inositol in place.
Subsequent work has revealed GCase bound to reversible
iminosugar inhibitors including isofagomine (IFG) [35],
N-butyl and N-nonyl deoxynojirimycin (NB- and NN-DNJ,
resp.) [36], and the bicyclic fused ring 6-amino-6-deoxy-
5,6-di-N-(N -octyliminomethylidene) nojirimycin [37]
(Figures 3(f)–3(h)). Whereas the structure of GCase with
IFG was solved by soaking the compound into a crystal
of deglycosylated Cerezyme, the latter structures were
obtained by cocrystallization with prGCase under oil. No
global changes are observed in the GCase structure upon
compound binding, but several changes are observed in
these structures that provide insight into a likely mode
for GlcCer binding. First, in all four structures, three of
which are presented in Figure 3, the compounds are held in
the active site by extensive hydrogen bonding interactions
with the hydroxyl and hydroxymethyl substituents (Figures
3(f)–3(h)). Compared to the IFG and DNJs (Figures 3(f)
and 3(g)), the bicyclic analog (Figure 3(h)) lacks the hydrox-
ymethyl arm, and instead, a fourth hydroxyl group is within
hydrogen bonding distance of Glu 235. In all cases, Asn 396,
but not Phe 397, is present in the active site and participates
in stabilizing the inhibitor. Second, compared to the sulfate
or glycerol-bound structures (Figures 3(c) and 3(d)) the
position of Tyr 313 has moved and is now in hydrogen
bonding distance of Glu 340 instead of Glu 235. Third,
the placement of the endocyclic nitrogen in each of these
compounds is informative. The secondary amine present in
the piperidine ring of IFG appears to mimic the position of
the anomeric carbon of GlcCer and positions Glu 340 and
Glu 235 for hydrolysis. Thus, IFG is a candidate transition
state inhibitor [68] or product mimic [35]. Notably, due to
its high pKa of 8.4 [69], IFG is likely protonated. By contrast,
the tertiary amines found in the DNJ analogs are shifted
with respect to the amine of IFG. The position of amines in
DNJ and bicyclic analogs mimic the endocyclic oxygen of
the glucose headgroup of GlcCer, and they do not make any6 Enzyme Research
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(a)
Phe 347
Tyr 348
(b)
Asn 396
Phe 397
Arg 395
Asn 396/
Phe 397
(c)
Figure 4: Superposition of GCase loops 1–5 in vicinity of active site. (a) Overlay of all loops, (b) detailed comparison of loop 2, and (c)
detailed comparison of loop 3. Colors are the same as in Figure 3 with the addition of grey for NN-DNJ (PDB code 2V3E).
contacts with GCase. The pKa of this nitrogen is ∼7[ 36]a n d
thus may also be protonated at low pH of the lysosome and
crystallization condition. The conﬁguration of the bound
DNJs indicates that they are not transition state mimics for
GCase. Lastly, positions of the hydrophobic tails are also of
interest, as they mimic the ceramide portion of GlcCer. The
alkyl tails of NB- and NN-DNJ appear to be stabilized by
interactions with Tyr 313 and another hydrophobic residue
outside the immediate active site, Leu 314 (not shown) [36];
unfortunately, no electron density was visible for the alkyl
chain of the fused bicyclic analog for comparison [37].
On the basis of the GCase structures with bound
inhibitors, some details of GCase catalysis can be conﬁrmed.
First, Glu 235 and Glu 340 are separated by 5 ˚ A, as expected
of a retaining glycosidase [21]. Second, whereas direct nucle-
ophilic attack of Glu 340 on the anomeric carbon of GlcCer
has been suggested [21], in the IFG-bound GCase structure,
the piperidine nitrogen is 2.7 ˚ A away from Glu 340 and Glu
235, a length more consistent with hydrogen bonding. Direct
attack of a Glu 340 might be prevented by the presence of
the apical hydrogen on the anomeric carbon in this position
of GlcCer [36], but it is certainly possible that IFG is not
a suitable analog to investigate such mechanistic details. By
contrast, nucleophilic attack on CBE can be envisioned more
readily because the hydrogen atom is not apical, thus reduc-
ing steric hindrance [33]. Third, a planar intermediate is also
anticipated[25].Asobserved withthebicyclicinhibitor [37],
this can be accommodated readily in the active site. In spite
of these views of bound inhibitors, several questions remain
openforinvestigation,includingtheprotonationstateofGlu
235 as well as the potential role of water in catalysis [36].
2.5.L oopsintheV icinityo ftheA cti veSite. Whereasthesiteof
catalysis is well-deﬁned in GCase, the hydrophobic binding
sites for ceramide are less clear. Indeed, the need for such a
bindingsiteisnotobviouslynecessary,giventheproximityof
GCase to the lysosomal lipid membrane, but speciﬁc subsites
were predicted from studies of human spleen-derived GCase
[28]. Initially, based on the ﬁrst crystal structure, which
lacked a hydrophobic surface for such binding, it was
proposed that the glucose moiety is bound in the active site,
with ceramide protruding out of the protein and into the
presumedlipidbilayer[24].Nevertheless,thepresenceofﬁve
loops(Figure4),Loop1(residues311–319),Loop2(residues
345–349) and Loop 3 (residues 394–399), but also Loop 4
(237–248)andLoop5(283–288)cappingtheactivesite,sug-
gestedthatrearrangementsmightbepossibleand,ifso,could
reveal a new binding site. The extent of the mobility of these
loops appeared minor at ﬁrst, however. GCase structures
solved to date overlay particularly well in loop 1 and loop
5 (Figure 4(a)), and crystal contacts in loop2 (Figure 4(b),
Phe 347- Trp 348) and loop 2 (Figure 4(c)) may preclude the
observation of ﬂuctuations that take place in solution.
The IFG-bound GCase structure was the ﬁrst to reveal
a substantial rearrangement of Loop 1 from an extended
to an α-helical turn [35] (Figures 5 and 6). This result
was surprising because loop 1 consists of residues that are
primarily hydrophobic and thus already match the charge of
the expected ceramide moiety in this region. The interplay
between the amphipathic residues, Trp 312 and Tyr 313,
and the one acidic residue, Asp 315, appears to be key
adopting the conﬁgurations observed (Figure 5). Asp 315
undergoes the furthest translation in the shift from helical
to extended loop 1. In the extended conformation (Figures
5(a) and 5(b)), loop 1 reaches toward loop 2, forming
hydrogen-bonding interactions with the main chain of Gly
344 (Figure 6(a)), whereas in the helical conformation, Asp
315istuckedwithinthecoreregionofGCase,formingwater-
mediated hydrogen bonding interactions with the clinically
important residue Asp 370 (Figure 5(c)) and a salt bridge
with the guanidinium group of Arg 285 (Figure 6(b)). Tyr
313, mentioned earlier with regard to ligand binding in the
active site, is also located on this loop, and another residue
to participate in hydrogen bonding. Tyr 313 swaps hydrogen
bonding partners from Glu 235 to Glu 340 (compare
Figure 3(c) to Figure 3(f)). For a ligand to bind in the GCase
active site it is tempting to envision an order of events in
which a change occurs in the hydrogen bonding patternEnzyme Research 7
Tyr 313
Asp 315
Trp 312
(a)
Tyr 313
Asp 315
Trp 312
(b)
Tyr 313 Asp 315
Trp 312
IFG
(c)
Figure 5: Loop 1 extended and helical conformations: surface view.
(a) Extended conformation, overlay of sulfate-bound and glycerol-
bound coordinates in this region. (b) Extended conformation
found for N370S-mutant GCase (PDB code 3KE0). (c) Helical
conformation depicted using coordinates of IFG-bound GCase.
Dashed lines are as in Figure 3.
of Tyr 313, which in turn disrupts the hydrogen bonding
pattern for Asp 315 and enables the loop to take on the new
helical conﬁguration. In terms of Trp 312 (Figure 6), in the
extended conformation, it is tucked under loop 1 and forms
hydrogen bonding interactions with Arg 285 (Figure 6(a));
this is the same relative placement of Asp 315 in the helical
turn (Figure 6(b)). In the helical conformation, Trp 312
swings out instead to form a hydrogen bonding interaction
with the main chain of Cys 342 (Figure 6(b)). Although
the positions of these residues are generally consistent given
a loop 1 conﬁguration, two exceptions include the N370S-
GCase structure (extended loop 1) [32], in which both Trp
312 and Trp 378 are within hydrogen bonding distance of
Ser 370 (Figure 6(c)), and apo GCase (helical loop 1) [38], in
which the same tryptophan residues are in contact with Asn
370 (Figure 6(d)).
The helical conformation has been observed in the
structures of the DNJ analogs [36], as well as in select
apo structures of Cerezyme [38] and Velaglucerase-alfa [30]
under diﬀerent pH conditions, indicating that loop 1 is
mobile both at pH 4.5 reminiscent of the lysosome and at
higher pH values of the ER. Speciﬁcally, in apo structures,
half of the molecules in the asymmetric unit are in the
extended and other in the helical conformation. It is not
currently known whether GCase, which appears to be a
functional dimer [70, 71], can only take on one helical
conformation at a time, or if this observation is trapped by
crystal packing [38]. Comparison of the thermal B-factors
reveals that the IFG-bound loop 1 conformation, with its
additional secondary structure, is better locked in position
than when present as an extended loop [35, 38].
The proposal that the conﬁguration of GCase loop 1
observed crystallographically when IFG is bound is the
activeconformationofGCaseissupportedbycomputational
docking studies. First, docking of drug fragments onto the
original GCase structure with an extended loop 1 predicts a
binding site that apparently clashes with this loop 1 arrange-
ment (Figure 7(a)), whereas docking with the helical loop 1
results in a similar cluster but without clashes (Figure 7(b))
[72]. This result is especially n otable in that the algorithm
used for docking provides for only minimal perturbation in
the receptor coordinates [72]. Second, simulations of GlcCer
docking using a truncated ceramide to limit degrees of free-
domplacethehydrophobictailsinthetwosubsitesemerging
from the catalytic center. A reasonable pose, in which the
glucose head group is well positioned with respect to the cat-
alytic residues, is only observed when using a receptor with
helical loop 1 [35] (Figure 7(c)). The glucose moiety is not
properly positioned when the extended loop 1 is present in
the receptor. A surface representation of this receptor reveals
that the active site covers the much smaller glycerol molecule
and thus is inaccessible to larger ligands (Figure 7(d)).
2.6. Eﬀects of Disease-Causing Mutants. Prior to the obser-
vation of the loop 1 helical conformation, it was diﬃcult
to reconcile how Asn 370, a residue 13 ˚ A from the catalytic
glutamateresidues,couldreduceenzymaticactivitybynearly
80% [16]. With the N370S-mutant GCase structure in hand,
we now know that only the extended loop 1 is observed at
both acidic and neutral pH [32]. Overall, the structure is
more rigid and exhibits minor stability changes compared to
wild-typeGCasewithnopH-dependentchangesobservedin
structure or circular dichroism spectrum [32]. As expected
for the extended loop, Tyr 313 is hydrogen bonded to Glu
235, but some changes are observed in the interior region,
as described above, with Trp 312 and Trp 378 (Figure 6(c)).
Theimplicationsofthishydrogenbondingshiftarenotclear,8 Enzyme Research
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Figure 6: Loop 1 extended and helical conformations: interior view. (a) Extended conformation, overlay of sulfate-bound, glycerol-bound,
and CBE-bound coordinates in this region. (b) Helical conformation using coordinates of IFG-bound GCase, NB-DNJ, and NB-DNJ. (c)
N370S-mutant GCase. (d) apo-GCase. Dashed lines and color schemes are the same as in Figure 3.
but given that this amino acid change is accompanied by
decreased enzyme activity and a disease state, the apparent
preference of an extended loop 1 in N370S-GCase is likely
intimately related to eﬃciency of GCase catalysis.
Among the mutants selected for highlight in Figure 2,
N370S is the best understood to date. Due to the discon-
tinuous nature of the domains with respect to amino acid
sequence, disease-causing residues close in sequence can be
found in diﬀerent GCase domains, with diﬀerent conse-
quences. Mysteries remain for mutations such as G202R,
D409H, and L444P, which lead to diﬀerent manifestations
of neuropathogenic GD. In the case of Gly 202, located
on a surface loop of Domain 2, there appears to be no
immediate shape or charge constraints. Located on a short
helical segment between two strands of Domain 1, Asp
409 participates in hydrogen bonding interactions with
the backbone nitrogen and side chains of Ser 97. At ﬁrst
glance, it would appear that histidine could participate in
similar interactions but upon closer inspection, the presence
of adjacent proline residues, Pro 98-99, suggests that this
interacting loop is rather rigid. Leu 444 is located on a loop
withinDomain3andisinvolvedinhydrophobicinteractions
with a cluster of leucines in its vicinity. Mutation to a proline
would be expected to rigidify the protein backbone and
perhaps propagate to a signiﬁcant new location for another
residueontheloop,suchasSer439,whichisinvolvedinboth
main chain and side chain interactions with a nearby strand.
Overall, it is not possible to predict severity of disease based
on location in GCase, nor is the eﬀect readily rationalized
based on the chemical environment of the residue. Solution
biophysical studies and additional structures of disease-
relevant mutant GCases would assist in understanding
structuralandstabilitydefectsthatmaycontributetodisease.
2.7. Glycosylation Sites. The endogenous human GCase
enzyme is glycosylated at 4 of 5 available asparagine residues,
andglycosylationisimportantfortheformationoftheactive
enzyme [73]. Cerezyme, Velaglucerase-alfa, and prGCase
have diﬀerent glycans due to their diﬀerent manufacturing
processes and their engineering for targeting to and uptake
by macrophages using the mannose receptor pathway. The
carrot-cell-expressed prGCD exhibits unique, plant-derivedEnzyme Research 9
Asp 315
Glu 235
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Figure 7: Computational docking and surface representations of GCase. (a) In silico fragment drug screening using extended loop 1 (yellow
cluster clashes with receptor coordinates). (b) In silico fragment drug screening using helical loop 1 (no clashes observed). (c) Surface
representation of IFG-bound GCase with ball-and-stick representation of truncated GlcCer computationally docked into the IFG-bound
GCase coordinates. (d) Surface representation of glycerol-bound GCase. Glycerol is presented in ball-and-stick to illustrate the limited
extent to which the active site is accessible.
glycan cores, including α-(1,2)-xylose and α-(1,3)-fucose.
The enzyme is targeted to the vacuole, leading to GCase
with terminal mannose [29]. To enhance its internalization
by macrophages, the CHO-cell-derived Cerezyme is sequen-
tially delgycosylated to leave the core glycan consisting of
2 N-acetyl-glucosamine and 3 mannose sugars [3]. In the
crystal structure of Cerezyme not subjected to treatment by
N-glycosidase F [34], ﬁve sugars are observed attached to
Asn 19, three on Asn 59, and two on Asn 146. No sugars
are observed bound to Asn 270 likely due to disorder in
the crystal [34], nor Asn 462, a buried residue conﬁrmed
earlier to lack glycosylation [73]. High resolution mass
spectrometry data reveals that Cerezyme contains ∼0.6 mole
M6P per enzyme and core structures that terminate in N-
acetyl-glucosamine, as well as some microheterogenetity at
Asn 59, Asn 146, and Asn 270 that includes fucosylation
and phosphorylation of high mannose carbohydrates [30].
SimilaranalysisofVelaglucerase-alfareveals0.8moleofM6P
and predominantly nine mannose units. At Asn 59, Asn 146,
and Asn 270, mono-siaylation and complex type structures
with core fucosylation, as well as phosphorylation, were
also observed at lower levels [30]. Compared to Cerezyme,
Velaglucerase-alfa is internalized to macrophages 2.5-fold
faster, likely a result of the diﬀerent glycosylation patterns
[30].
2.8. Anion Binding Sites. GCase is associated with the
lysosomal membrane in vivo [74], and negatively charged
phospholipids are required for optimal activity in vitro
[28, 31, 74], suggesting that speciﬁc binding sites for anions
may be present on GCase. Several such binding sites can be
inferred from bound phosphate and sulfate anions modeled
inthesolvedstructures,whicharisefromthesaltsusedinthe
crystallization solution. In particular, among the structures
of Cerezyme, Velaglucerase-alfa, and prGCase, there are
seven apparent anion binding sites (Figure 8). A particular
cluster of note contains three binding sites, corroborated
among the various structures and is found on Domain 3
on the same face as the GCase active site in Domain 2. The
anionsareheldinplacebySer12,Ser23,Arg44,Arg353,Ser
356, Tyr 487, and the backbone nitrogens of Ser 45, Trp 357,
andAsp358(Figure8circled).Thissitemaybeimportantfor
phospholipid binding and membrane association [34]. The
other anion binding sites, scattered on the GCase surface,
appear to have just one anion bound, suggesting that these
may be nonspeciﬁc binding sites.10 Enzyme Research
Table 2: Structures of saposin C.
PDB code Enzyme source Detergent? Technique Experimental summary Citation
1M12 E. coli No NMR 15N, 1H, and 13C heteronuclear NMR experiments [45]
1SN6 E. coli Yes, SDS NMR 15N, 1H, and 13C heteronuclear NMR experiments [75]
2GTG E. coli No Crystallography Calciumchloride,HepesbuﬀerpH7orcacodylate
buﬀer pH 6, glycerol cryoprotectant
[78]
2QYP P. pastoris No Crystallography Magnesium sulfate or ammonium sulfate, acetate
buﬀer pH 4, pentaerythritol ethoxylate 15/4
[50]
2Z9A P. pastoris No Crystallography Same as 2QYP [50]
Glu 340
Glu 235
Figure 8: Anion binding sites on GCase. Sulfate or phosphate
anions are presented in yellow ball-and-stick; interacting residues
are presented in orange; active site residues Glu 235 and Glu 340 are
labeled as well. Circled: cluster of several anions that may represent
an anionic lipid binding site.
3. Structureof SaposinC
3.1. Protein Sources. The structure of SapC has been deter-
mined by both NMR and X-ray crystallographic techniques
using recombinant SapC puriﬁed from E. coli [45, 75]o r
P. pastoris [50, 76]. Since the writing of the most recent
review article dedicated to saposin structure [77], several
new structures of SapC have arisen using both techniques
under diﬀerent chemical environments. Table 2 summarizes
the available SapC structures.
3.2. Structure Determination. The ﬁrst solution NMR struc-
ture of SapC was solved at pH 4 and pH 7 using a suite
of heteronuclear NMR experiments to determine distance
restraints and dipolar couplings [45]. The subsequent
solution structure was determined by similar methods in
the presence of 25mM sodium dodecyl sulfate (SDS),
perdeuterated as necessary. The coordinates of the ﬁrst NMR
structure were used as a molecular replacement model to
solve the ﬁrst 2 ˚ A resolution crystal structure. These crystals
were grown from a solution at pH 6 or 7 and belong to the
hexagonal space group P63 (approximate unit cell dimen-
sions a=b= 53 ˚ A, c = 52.5 ˚ A, β = 120◦,a n do n em o l e c u l e
in the asymmetric unit) [78]. Additional crystal forms of
SapC have been solved at pH 5 [50]: tetragonal (P41212,
unit cell dimensions a=b= 49 ˚ A, c = 155.6 ˚ A, all angles 90◦,
2 molecules in asymmetric unit) and orthorhombic (C2221,
unitcelldimensions57,89,93.5 ˚ A,allangles90◦,2molecules
in asymmetric unit), using coordinates of the ﬁrst reported
crystal structure.
3.3. Overall Structure. Solution NMR [45, 75]a n dX - r a y
c ry s t a ls t r u c t u r e s[ 50, 78] reveal a ﬂexible SapC (Figure 9(a))
composed of 4 or 5 amphipathic helices, two pairs of which
are disulﬁde bonded. SapC adopts two main conﬁgurations:
(a) “closed” helical bundle (Figures 9(b) and 9(c))a n d( b )
“open,”boomerangshapewitharangeofobtusehingeangles
(Figures 9(d)–9(f))[ 50] that reveal a hydrophobic surface.
Lipid binding to SapC is not fully understood. Lipids are
proposed to bind only after neutralization of the negative
electrostatic surface by a pH-controlled reversible process
[45, 76] but which, if any, of the available structures is
biologically functional is unclear. For the SapC monomer,
no structural change was detected by NMR upon binding
to phospholipid vesicles [45] ,b u ta no p e ns t r u c t u r ew a s
observed with the addition of SDS [75]. To complicate
matters, SapC has been shown to be a dimer [76]a n d
trimer in solution at low pH [78], and two of the available
crystal structures solved near neutral pH are the domain-
swapped dimers (Figure 9)[ 50]. The bundled monomer
and dimeric species shield a hydrophobic surface; one
method to elicit a conformational change upon lipid binding
would be via its interactions with positively charged lysine
residues that would propagate to expose this hydrophobic
surface. Alternatively, the extended dimer could be func-
tional,witheachendparticipatinginmembraneinteractions
[50, 79].
4. Complex of GCaseandSaposinC
In spite of the evidence that stresses the importance of SapC
for GCase enzyme activity and their genetic mutations that
lead to GD, the speciﬁc site of their presumed interaction has
not been explicitly established. Work towards understanding
the interaction includes experiments localizing the SapC
binding site in the proximity of N370 [80], investigating
interactions with site-directed mutants of SapC [49, 81]a n d
through investigations using model peptides derived from
the SapC sequence [82]. A computation docking model [83]
utilizing the closed or open SapC coordinates from NMR
(PDB code 1M12 or 1SN6, resp.) and those correspondingEnzyme Research 11
(a) (b) (c) (d)
(e) (f)
Figure 9: Structures of SapC. (a) Overlay of structures presented in (b)–(f) colored in a rainbow from N-terminus (blue) to C-terminus
(red). (b) Closed NMR structure (PDB code 1M12). (c) Closed crystal structure (PDB code 2GTG). (c) Open NMR structure (PDB code
1SN6). (d) Open crystallographic dimer (orthorhombic, PDB code 2Z9A). (e) Open crystallographic dimer (tetragonal, PDB code 2QYP).
(a) (b)
Active site
(c)
Figure 10: Interaction surfaces for GCase-SapC complex identiﬁed by computational docking. (a) Closed NMR structure, (b) open NMR
structure, and (c) sulfate-bound GCase each with proposed interacting residues in ball-and-stick (left) and highlighted blue in surface
representation on right.
to the ﬁrst GCase structure (extended loop 1, PDB code
1OGS) reveals a localized surface that includes interactions
from both domains 1 and 2 of GCase and a cluster on
SapC (Figure 10). This model correlates reasonably well
with experimental ﬁndings that a peptide composed of
residues 41–82 binds best to GCase [82] and that residues
important for GCase activation are localized to residues 47–
62. Similar computational docking calculations with GCase
in its active conformation might provide additional strength
to the identiﬁcation of this binding interface.12 Enzyme Research
5. FutureDirections
The structures of GCase and SapC have been very valuable
to conﬁrm experimental observations. Assisted by com-
putational modeling of interactions, new structure-based
hypotheses for additional experiments, as well as inspire
rational drug design and discovery have emerged. Still, many
questionsremaintobeaddressedbysolutionbiophysicaland
structural studies, which include, but are not limited to the
following.
(i) Lysosomal Traﬃcking: is LIMP-II the universal lyso-
somal chaperone for GCase? If so, it is likely that a
stable interaction forms between these two proteins,
and characterization of the complex could provide
new insight into ways to favor traﬃcking of mutant
GCases over their degradation by stabilizing the
interaction with LIMP-II.
(ii) Structural aspects of GCase: is the helical loop 1 as
critical for catalysis as proposed? Structures with
nonhydrolysable substrate analogs or additional
inhibitors could continue to provide insight into
GLCase catalysis, the plasticity of the GCase active
site, and ways in which remotely located mutations
could impair enzyme activity.
(iii) Eﬀects of mutations on GCase: why are certain muta-
tions pathogenic if they yield enzymes in vitro? Both
structural and modeling studies of speciﬁc mutants
could provide additional insight into these defects.
(iv) Structural aspects of SapC: to what extent are
the available structures functionally relevant?
How does lipid bind and what is the mechanism
of solubilization by SapC? The characterization
additional constructs, such as those containing
disease-causing mutations, may provide new insight
into the ﬂexibility of SapC upon lipid binding.
(v) Complex between GCase and SapC: what is the
aﬃnity of these proteins for each other? What
components, such as lipids, substrate, or membrane,
might also be critical to detect as stable interaction,
if formed? With all of the components in place it
may be possible to isolate a complex for structure
determination. If the interaction is transient, what is
the rationale?
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